Additional benefits by share of subpopulations

The G-BA has so far determined 1966 patient-specific subpopulations. 1.2% of these subpopulations have been seen as providing a major additional benefit for the patients and a further 12.1% as delivering a considerable additional benefit. A minor additional benefit was seen for about 12.7% of the subpopulations, while the additional benefit was not quantifiable for about 18.3% of the subpopulations. The G-BA determined no indication-specific benefit in about 54.4% of all subpopulations. Less benefit compared to the appropriate comparative therapy was seen in 0.3% of the subpopulations.